Lexicon reports FDA's decision to extend review period for Zynquista

Core Viewpoint - Lexicon Pharmaceuticals is facing a delay in the FDA review process for the marketing application of Zynquista (sotagliflozin) intended for adults with type 1 diabetes due to the request for additional time to review further clinical data [5] Group 1 - The FDA has requested additional time for the review of the marketing application for Zynquista [5] - The request for more time is related to the submission of additional clinical data [5]